Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy blood-forming cells. If the disease recurs after treatment or fails to respond, CAR ...

CAR-T is a powerful tool which is still evolving. Here we highlight what is new in CAR-T cell therapy Cancer cells often play hide-and-seek with the immune system in an attempt to evade catastrophic ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ...